
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
QNTM | CSE | CAD | Delayed | |
QNTM | NASDAQ | USD | Real-time | |
QNTM | CBOE Canada | CAD | Real-time | |
0K91G | Frankfurt | EUR | Delayed |
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Zeeshan Saeed | 55 | 2021 | Founder, CEO, President & Executive Co-Chairman |
Daniele Piomelli | - | 2022 | Member of Research & Clinical Advisory Board |
Peter K. Stys | - | 2021 | Member of Research & Clinical Advisory Board |
Eleanor N. Fish | - | 2021 | Member of Research & Clinical Advisory Board |
Shannon Dunn | - | 2021 | Member of Research & Clinical Advisory Board |
Hance Clarke | - | 2021 | Member of Research & Clinical Advisory Board |
Kwok Chow | - | 2022 | Member of the Regulatory Advisory Board |
David G. P. Allan | 83 | 2022 | Member of Advisory Board |
Alexander Bar | - | 2023 | Member of Advisory Board |
Lakshmi P. Kotra | 54 | 2021 | CEO of Lucid & Director |
Joga Gobburu | - | 2021 | Member of Regulatory Advisory Board |
Anthony John Durkacz | 49 | 2018 | Founder & Executive Co-Chairman |
Mary Melnyk | - | 2021 | Member of Regulatory Advisory Board |
Ravinder Kumar | - | 2022 | Member of Advisory Board |
Albert H.C. Wong | - | 2021 | Member of Research & Clinical Advisory Board |
Gerald V. David | 73 | 2023 | Member of Advisory Board |
Eric William Hoskins | 63 | 2023 | Independent Director |
Adnan Bashir | 55 | 2021 | Independent Director |
Navdeep Jaikaria | 62 | - | Member of Advisory Board |
Kevin Harrington | 68 | 2023 | Member of Advisory Board |
John McGraw | - | 2022 | Member of Advisory Board |
Michael Zapolin | 58 | 2023 | Independent Director |
Terrence Lynch | 65 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review